NCT04221555已完成2 期
Neoadjuvant Durvalumab (MEDI4736) Plus Docetaxel, Oxaliplatin, S-1 (DOS) Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient (pMMR) Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 68
- 试验地点
- 1
- 主要终点
- Pathologic complete regression (pCR) rate
研究概览
简要总结
Neoadjuvant durvalumab (MEDI4736) plus docetaxel, oxaliplatin, S-1 (DOS) followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in potentially resectable MMR proficient (pMMR) gastric or gastroesophageal junction (GEJ) adenocarcinoma
详细描述
- Treatment for the main treatment group (pMMR tumor)
- Neoadjuvant treatment Durvalumab 1120 mg IV on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles.
- Surgery
- Adjuvant treatment After 4-6 weeks from surgery, S-1 40 mg/m2 bid orally on D1-28 plus durvalumab 1120 mg on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment.
- Treatment for the exploratory group (dMMR tumor)
- Neoadjuvant treatment Durvalumab 1500 mg IV and tremelimumab 75 mg IV on D1 will be administered every four weeks for three cycles.
- Surgery
- Adjuvant treatment After 4-6 weeks from surgery, durvalumab 1500 mg on D1 will be administered every 4 weeks for 12 months as an adjuvant treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Newly diagnosed pathologically proven potentially resectable gastric or GEJ adenocarcinoma
- •Clinical stages of T3-4N0 or T2-4N+ according to the American Joint Committee on Cancer (AJCC) 8th edition by computed tomography (CT)
- •Microsatellite-instability (MSI) status determined by immunohistochemical (IHC) staining
- •No peritoneal seeding identified by laparoscopy if suspected by CT
- •Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations
- •Age > 18 years at time of study entry
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Life expectancy of > 12 months
- •Body weight > 30kg
- •No existing neuropathy
- •Adequate normal organ and marrow function as defined below:
- •Haemoglobin ≥9.0 g/dL
- •Absolute neutrophil count (ANC) 1.5 (or 1.0) x (> 1500 per mm3)
- •Platelet count ≥100 (or 75) x 109/L (>75,000 per mm3)
- •Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN)
- •AST (SGOT)/ALT (SGPT) ≤2.5 x institutional ULN
- •Measured creatinine clearance (CL) > 40 mL/min or Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:
- •Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.
- •Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
排除标准
- •Participation in another clinical study with an investigational product during the last 2 weeks
- •Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
- •Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacementtherapy) is acceptable
- •Major surgical procedure within 28 days prior to the first dose of durvalumab
- •Distant metastasis including M1 lymph node
- •Unable to take medication orally
- •Gastric outlet obstruction and/or severe gastrointestinal bleeding
- •Impaired bowel absorption, including any of the following:
- •Bowel obstruction
- •Chronic inflammatory bowel disease
- •History of extended bowel resection
- •Gastric dumping syndrome
- •History of allogenic organ transplantation
- •Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
- •Patients with vitiligo or alopecia
- •Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
- •Any chronic skin condition that does not require systemic therapy
- •Patients without active disease in the last 5 years may be included but only after consultation with the study physician
- •Patients with celiac disease controlled by diet alone
- •Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events (AEs) or compromise the ability of the patient to give written informed consent
- •History of another primary malignancy except for
- •Malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of durvalumab and of low potential risk for recurrence
- •Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- •Adequately treated carcinoma in situ without evidence of disease
- •Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart)
- •History of active primary immunodeficiency
- •Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
- •Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:
- •Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
- •Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
- •Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
- •Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab. Note: Patients, if enrolled, should not receive live vaccine whilst receiving durvalumab and up to 30 days after the last dose of durvalumab
- •Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab
- •Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
- •Prior randomisation or treatment in a previous durvalumab or tremelimumab clinical study regardless of treatment arm assignment
研究组 & 干预措施
the exploratory group
Active Comparator
dMMR tumor
干预措施: Durvalumab and Tremelimumab (Drug)
the main treatment group
Experimental
pMMR tumor
干预措施: Docetaxel, Oxaliplatin, S-1 and Durvalumab (Drug)
结局指标
主要结局
Pathologic complete regression (pCR) rate
时间窗: 3 years
次要结局
- R0 resection rate(3 years)
- Disease free survival (DFS)(3 years)
研究者
Min-Hee Ryu
Professor
Asan Medical Center
研究点 (1)
Loading locations...
相似试验
招募中
不适用
eoadjuvant durvalumab (MEDI4736) plus docetaxel, oxaliplatin, S-1 (DOS) followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in potentially resectable MMR proficient (pMMR) gastric or gastroesophageal junction (GEJ) adenocarcinomaNeoplasmsKCT0004390Asan Medical Center68
已完成
不适用
Docetaxel and Trastuzumab therapy or maximal androgen blockade for patients with recurrent and/or metastatic salivary grand carcinomaHER2 and/or androgen receptor positive recurrent and/or metastatic salivary gland carcinomaJPRN-UMIN000009437International University of Health and Welfare Mita Hospital30
进行中（未招募）
不适用
Docetaxel plus Atezolizumab plus Herceptin SC and Pertuzumab for Patients with Early Breast Cancer and Atezolizumab plus Herceptin SC and Pertuzumab chemotherapy after SurgeryKCT0003774Samsung Medical Center67
进行中（未招募）
2 期
Docetaxel plus Ramucirumab immediately after treatment with ICInon-small cell lung cancer, adenocarcinoma, squamous cell carcinomanon-small cell lung cancerJPRN-jRCT1051190091Akamatsu Hiroaki35
进行中（未招募）
1 期
Treatment to modulate the activity of the immune system in combination with chemotherapy treatment in patients with operable urothelial cancerEUCTR2017-003565-10-DESwiss Group for Clinical Cancer Research61